STOCK TITAN

Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Dynavax Technologies (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on innovative vaccines, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024, after U.S. financial markets close. The company will host a conference call and live audio webcast on the same day at 4:30 p.m. ET/1:30 p.m. PT.

Investors can access the live audio webcast through the 'Events & Presentations' page on the company's website. A replay will be available for 30 days following the event. To participate in the call, attendees must register using the provided caller registration link. It is recommended that participants join the conference call or webcast approximately 10 minutes before the scheduled start time.

Dynavax Technologies (Nasdaq: DVAX), un'azienda biotecnologica in fase commerciale specializzata in vaccini innovativi, ha annunciato che riporterà i propri risultati finanziari del secondo trimestre 2024 martedì 6 agosto 2024, dopo la chiusura dei mercati finanziari statunitensi. L'azienda ospiterà una conferenza telefonica e una diretta audio sul web lo stesso giorno alle 16:30 ET/13:30 PT.

Gli investitori possono accedere alla diretta audio tramite la pagina 'Eventi e Presentazioni' sul sito web dell'azienda. Una registrazione sarà disponibile per 30 giorni dopo l'evento. Per partecipare alla chiamata, gli intervenuti devono registrarsi utilizzando il link di registrazione fornito. Si consiglia ai partecipanti di unirsi alla conferenza telefonica o alla diretta circa 10 minuti prima dell'orario di inizio previsto.

Dynavax Technologies (Nasdaq: DVAX), una compañía biofarmacéutica en etapa comercial centrada en vacunas innovadoras, ha anunciado que informará sobre sus resultados financieros del segundo trimestre de 2024 el martes 6 de agosto de 2024, después de que cierren los mercados financieros de EE. UU. La compañía llevará a cabo una conferencia telefónica y una transmisión de audio en vivo el mismo día a las 4:30 p.m. ET/1:30 p.m. PT.

Los inversionistas pueden acceder a la transmisión de audio en vivo a través de la página 'Eventos y Presentaciones' en el sitio web de la compañía. Una grabación estará disponible durante 30 días después del evento. Para participar en la llamada, los asistentes deben registrarse utilizando el enlace de registro de llamadas proporcionado. Se recomienda que los participantes se unan a la conferencia telefónica o a la transmisión aproximadamente 10 minutos antes de la hora de inicio programada.

다이나박스 테크놀로지스 (Nasdaq: DVAX), 혁신적인 백신에 중점을 둔 상업 단계의 생물 제약 회사가 2024년 2분기 재무 결과를 2024년 8월 6일 화요일 미국 금융 시장 폐장 후 발표한다고 발표했습니다. 이 회사는 같은 날 오후 4시 30분 ET/오후 1시 30분 PT에 컨퍼런스 콜 및 라이브 오디오 웹캐스트를 개최할 예정입니다.

투자자들은 회사 웹사이트의 '이벤트 및 발표' 페이지를 통해 라이브 오디오 웹캐스트에 액세스할 수 있습니다. 이 이벤트 이후 30일 동안 다시 시청할 수 있습니다. 콜에 참여하려면 참석자는 제공된 전화 등록 링크를 사용하여 등록해야 합니다. 참가자들은 예정된 시작 시간 약 10분 전에 컨퍼런스 콜 또는 웹캐스트에 접속하는 것이 좋습니다.

Dynavax Technologies (Nasdaq: DVAX), une entreprise biopharmaceutique en phase commerciale spécialisée dans les vaccins innovants, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le mardi 6 août 2024, après la fermeture des marchés financiers américains. L'entreprise animera une conférence téléphonique et un webinaire audio en direct le même jour à 16h30 ET/13h30 PT.

Les investisseurs peuvent accéder à l'audio en direct via la page 'Événements et Présentations' sur le site Web de l'entreprise. Une rediffusion sera disponible pendant 30 jours après l'événement. Pour participer à l'appel, les participants doivent s'inscrire en utilisant le lien d'inscription fourni. Il est recommandé aux participants de rejoindre la conférence ou le webinaire environ 10 minutes avant l'heure de début prévue.

Dynavax Technologies (Nasdaq: DVAX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf innovative Impfstoffe konzentriert, hat angekündigt, dass es am Dienstag, den 6. August 2024, nach Schließung der US-Finanzmärkte seine finanziellen Ergebnisse für das zweite Quartal 2024 vorlegen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr ET/13:30 Uhr PT eine Telefonkonferenz und einen Live-Audio-Webcast veranstalten.

Investoren können über die Seite 'Veranstaltungen & Präsentationen' auf der Website des Unternehmens auf den Live-Audio-Webcast zugreifen. Eine Aufzeichnung wird 30 Tage nach der Veranstaltung verfügbar sein. Um an der Telefonkonferenz teilzunehmen, müssen sich die Teilnehmer über den bereitgestellten Anmeldelink registrieren. Es wird empfohlen, dass die Teilnehmer etwa 10 Minuten vor der geplanten Startzeit der Konferenz anrufen oder sich zuschalten.

Positive
  • None.
Negative
  • None.

EMERYVILLE, Calif., July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

For Investors/Media:
Paul Cox 
pcox@dynavax.com
510-665-0499 

Nicole Arndt
narndt@dynavax.com
510-665-7264

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-second-quarter-2024-financial-results-and-host-conference-call-on-august-6-2024-302204457.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax (DVAX) report its Q2 2024 financial results?

Dynavax (DVAX) will report its second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets close.

What time is Dynavax's (DVAX) Q2 2024 earnings call scheduled for?

Dynavax's (DVAX) Q2 2024 earnings conference call and live audio webcast is scheduled for Tuesday, August 6, 2024, at 4:30 p.m. ET/1:30 p.m. PT.

How can investors access Dynavax's (DVAX) Q2 2024 earnings webcast?

Investors can access Dynavax's (DVAX) Q2 2024 earnings webcast through the 'Events & Presentations' page on the 'Investors' section of the company's website at https://investors.dynavax.com/events-presentations.

How long will the replay of Dynavax's (DVAX) Q2 2024 earnings webcast be available?

The replay of Dynavax's (DVAX) Q2 2024 earnings webcast will be available for 30 days following the live event.

Dynavax Technologies Corporation

NASDAQ:DVAX

DVAX Rankings

DVAX Latest News

DVAX Stock Data

1.35B
130.89M
0.34%
102.48%
13.66%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
EMERYVILLE